Chronic lymphocytic leukaemia (CLL) exhibits differences between Asians and Caucasians in terms of incidence rate, age at onset, immunophenotype, and genetic profile. We performed genomewide methylation profiling of CLL in an Asian cohort for the first time. Eight Korean patients without somatic immunoglobulin heavy chain gene hypermutations underwent methyl-cpG-binding domain sequencing (MBD-seq), as did five control subjects. Gene Ontology, pathway analysis, and networkbased prioritization of differentially methylated genes were also performed. More regions were hypomethylated (2,062 windows) than were hypermethylated (777 windows). Promoters contained the highest proportion of differentially methylated regions (0.08%), while distal intergenic and intron regions contained the largest number of differentially methylated regions. Protein-coding genes were the most abundant, followed by long noncoding and short noncoding genes. The most significantly over-represented signalling pathways in the differentially methylated gene list included immune/ cancer-related pathways and B-cell receptor signalling. Among the top 10 hub genes identified via network-based prioritization, four (UBC, GRB2, CREBBP, and GAB2) had no known relevance to cLL, while the other six (STAT3, PTPN6, SYK, STAT5B, XPO1, and ABL1) have previously been linked to cLL in Caucasians. As such, our analysis identified four novel candidate genes of potential significance to Asian patients with CLL. Chronic lymphocytic leukaemia (CLL) is characterized by the co-expression of CD5 and CD23 in monomorphic small B-cells; it is the most common leukaemia among adults in Western countries, especially the elderly 1. CLL among Asians differs from that among Caucasians in terms of the incidence rate, median age at onset, phenotype, and the genetic profile. The incidence rates per 100,000 person-years in Korea and Japan are 0.04 and 0.48, respectively, but the rate is 3.83 in Western countries 2. The median age at initial CLL diagnosis is 61 and 70 years among Asians and Caucasians, respectively 2. A single-institution study in South Korea found that 56% of patients had an atypical immunophenotype with high frequencies of FMC7 positivity and strong CD22 positivity 3. A Chinese study showed that TP53 mutations are more common in Chinese patients with CLL than in Caucasian patients, whereas SF3B1 mutations are less common 4. Furthermore, a Korean study found that the frequencies of mutations in ATM, TP53, KLHL6, BCOR, and CDKN2A tend to be higher in Koreans than in Caucasians, while those in SF3B1, NOTCH1, CHD2, and POT1 tend to be lower 2. DNA methylation directly impacts human genome function, and multiple studies have demonstrated the existence of aberrant epigenetic changes that play important roles in tumour initiation and progression in Western patients with CLL 5-8. Recent advances in high-throughput techniques have enabled genome-wide methylation profiling in Caucasians with CLL. For example, an array study identified methylation in seven known or candidate